Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.56 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5154461 | 1.00 | F2 (0.56) | F2FKBP1AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL2441194 | 0.84 | FKBP1A (0.60) | F2FKBP1AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL7452551 | 0.84 | FKBP1A (0.60) | F2FKBP1AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL7450338 | 0.83 | CACNA1G (0.60) | F2FKBP1AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL8544795 | 0.83 | FKBP1A (0.59) | F2FKBP1AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL8543317 | 0.80 | F2 (0.58) | F2FKBP1AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL8543599 | 0.80 | EPHX1 (0.54) | F2FKBP1AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL8545031 | 0.79 | ALDH1A1 (0.61) | F2FKBP1AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL13995293 | 0.78 | ALDH1A1 (0.60) | F2FKBP1AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL24820758 | 0.78 | CYP3A4 (0.64) | F2FKBP1AALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745019-A1 | NOVEL COMPOUNDS OF PROLINE AND MORPHOLINE DERIVATIVES | PFIZER INC. (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CHENG HENGMIAO | 2005-11-24 | — | — | US | disclosed |
| WO-2005108359-A1 | NOVEL COMPOUNDS OF PROLINE AND MORPHOLINE DERIVATIVES | PFIZER INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CYP11B1, HSD11B1, CYP11B2 | F2 1171/4885FKBP1A 33/4885ALDH1A1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.